AB-202 (Artiva Biotherapeutics)

N/A

Report date: 2024/12/12 11:34:43

Base Information

Drug NameAB-202 (Artiva Biotherapeutics)

Drug Alias NameCD19 CAR-NK Cell Therapy (Artiva Biotherapeutics)GCC2004GCC-2004AB-202 (Artiva Biotherapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesArtiva Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesArtiva Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A